Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline added to Aricept in mild to moderate Alzheimer's Disease
NCT00104273Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2004
- Primary completion
- Mar 2007
- Countries
- 4
- Modality
- Irreversible Covalent Inhibitors
- Drugs
- rasagiline
- Conditions
- Alzheimer's disease (AD)
01
Overview
Phase 2, randomised, double-blind trial of rasagiline in Alzheimer's disease (AD) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Cognitive Function. Started Aug 2004; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Rasagiline 1 mg
Rasagiline 1 mg + Aricept 10 mg
Rasagiline 2 mg
Rasagiline 2 mg + Aricept 10 mg
Placebo
Placebo + Aricept 10 mg
03
Who it enrols
Patients with mild-to-moderate Alzheimer's Disease (MMSE 15-26) on a stable dose of Aricept 10 mg daily.
04
Endpoints
Primary
Cognitive Function
Secondary
Activities of Daily Living
Safety
Tolerability
Beyond the preview
Go deeper on NCT00104273.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00104273.